Generic Name

Enalapril

Brand Names
Vasotec, Epaned, Vaseretic
FDA approval date: December 24, 1985
Classification: Angiotensin Converting Enzyme Inhibitor
Form: Tablet, Solution

What is Vasotec (Enalapril)?

Hypertension Enalapril maleate tablets USP are indicated for the treatment of hypertension. Enalapril maleate tablets USP are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of enalapril maleate tablets USP and thiazides are approximately additive. Heart Failure Enalapril maleate tablets USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets USP improves symptoms, increases survival, and decreases the frequency of hospitalization. Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction , enalapril maleate tablets USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. In using enalapril maleate tablets USP consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets USP does not have a similar risk. In considering use of enalapril maleate tablets USP, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy

Summary: The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function and compare it to the currently used treatment with the angiotensin converting enzyme inhibitor, enalapril, in patients with the complement-mediated renal disease C3 glomeru...

Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril

Summary: Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study th...

A Single Center, Single Arm, Phase 2, Pilot Study to Investigate the Efficacy of the ACE Inhibitor Enalapril in Participants Aged 18-70 Years of Age With Painful Venous Malformations.

Summary: The goal of this clinical trial is to explore if enalapril can be used to treat painful venous malformations. The main question it aims to answer are: \- Can enalapril reduce pain and volume of the malformation and increase quality of life in patients with painful venous malformations? Participants will: Receive a dose of enalapril 5 mg once daily. If it doesn't have effect the dose of enalapril w...

Brand Information

    Vasotec (Enalapril Maleate)
    WARNING: FETAL TOXICITY
    See full prescribing information for complete boxed warning.
    • When pregnancy is detected, discontinue VASOTEC
    • Drugs that act directly on the renin-angiotensin system can cause injury and death to thedeveloping fetus. (SeeWARNINGS, Fetal Toxicity.)
    1DESCRIPTION
    VASOTEC
    Chemical Structure
    Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.
    Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.
    Enalapril maleate is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each tablet contains the following inactive ingredients: lactose, magnesium stearate, sodium bicarbonate, and starch. The 10 mg and 20 mg tablets also contain iron oxides.
    2CONTRAINDICATIONS
    VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.
    Do not coadminister aliskiren with VASOTEC in patients with diabetes (see
    VASOTEC is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see
    3ADVERSE REACTIONS
    VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2987 patients. For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.
    4OVERDOSAGE
    Limited data are available in regard to overdosage in humans.
    Single oral doses of enalapril above 1,000 mg/kg and ≥1,775 mg/kg were associated with lethality in mice and rats, respectively.
    The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.
    Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis (see
    5PRINCIPAL DISPLAY PANEL - 2.5 mg Bottle Label
    NDC 0187-0140-30
    Rx Only
    Vasotec®
    (enalapril maleate)
    Tablets
    2.5 mg
    30 Tablets
    BAUSCH Health
    2.5mg
    6PRINCIPAL DISPLAY PANEL - 5 mg Bottle Label
    NDC 0187-0141-30
    Rx only
    Vasotec®
    (enalapril maleate)
    Tablets
    5 mg
    30 Tablets
    BAUSCH Health
    5mg
    7PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label
    NDC 0187-0142-30
    Vasotec®
    (enalapril maleate)
    Tablets
    10 mg
    30 Tablets
    BAUSCH Health
    10mg
    8PRINCIPAL DISPLAY PANEL - 20 mg Bottle Label
    NDC 0187-0143-30
    Rx only
    Vasotec®
    (enalapril maleate)
    Tablets
    20 mg
    30 Tablets
    BAUSCH Health
    20mg
    Vasotec has been selected.